Ventana Biotech, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VNTA research report →
About the company
Ventana Biotech, Inc. is an emerging biotechnology enterprise focused on the lifecycle of drug candidates for personalized medicine, encompassing the identification, assessment, acquisition, development, and eventual commercialization through partnerships of relevant intellectual property. The company's primary therapeutic area is addressing obesity and its associated medical conditions.
- CEO
- Janne Christensen
- IPO
- 2009
- HQ
- Denver, CH
Price Chart
- Market Cap
- $173.46K
- P/E
- 39.37
- P/S
- 1.51
- P/B
- -62.83
- EV/EBITDA
- 2.24
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 87.99%
- Net Margin
- 75.18%
- ROE
- -162.12%
- ROIC
- 145.45%
- Revenue
- $114.58K · 177.01%
- Net Income
- $86.14K · 333.08%
- EPS
- $0.00 · 300.00%
- Op Income
- $100.81K
- FCF YoY
- 0.00%
- 52W High
- $0.08
- 52W Low
- $0.02
- 50D MA
- $0.04
- 200D MA
- $0.04
- Beta
- -3.53
- Avg Volume
- 239
Get TickerSpark's AI analysis on VNTA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our VNTA coverage
Recent articles, reports, and earnings notes.
No research on VNTA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate VNTA report →Similar companies
Peers in the same neighborhood.